01:26 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest inhibiting the Wnt enhanceosome components BCL9, PYGO1 and/or PYGO2 could help treat APC-mutant colorectal cancer. In a mouse model of APC-mutant colorectal cancer, intestinal epithelium-specific knockout of BCL9, PYGO1...
18:33 , Oct 19, 2018 |  BC Week In Review  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
14:41 , Oct 15, 2018 |  BC Extra  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
02:36 , Aug 24, 2018 |  BC Innovations  |  Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
06:33 , Aug 10, 2018 |  BC Week In Review  |  Financial News

SQZ raises $72M series C

Cell therapy company SQZ Biotechnologies Co. (Watertown, Mass.) raised $72 million on Aug. 8 in an oversubscribed, untranched series C round. New investors Everblue, Illumina Ventures, Invus, Orient Life and Viva Ventures Biotech Group participated,...
12:33 , Aug 8, 2018 |  BC Extra  |  Financial News

SQZ raises $72M series C

Cell therapy company SQZ Biotechnologies Co. (Watertown, Mass.) raised $72 million in an oversubscribed, untranched series C round. New investors Everblue, Illumina Ventures, Invus, Orient Life and Viva Ventures Biotech Group participated, as did existing...
01:34 , Jun 22, 2018 |  BC Innovations  |  Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8 + T cells have grabbed most of the attention, a study...
20:12 , Feb 9, 2018 |  BC Week In Review  |  Company News

Advanced Proteome, ImmunoBiochem to develop ADCs for TNBC

Advanced Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8) and ImmunoBiochem Corp. (Toronto, Ontario) will evaluate combining an undisclosed antibody from ImmunoBiochem with Advanced Proteome's site-selective conjugation technology to develop antibody-drug conjugates (ADCs) to treat triple-negative breast cancer...
16:16 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

ZZ Biotech's 3K3A-APC reduces hemorrhage rate in Phase II for acute ischemic stroke

ZZ Biotech LLC (Houston, Texas) reported preliminary data from the Phase II RHAPSODY trial in 110 patients with moderate to severe acute ischemic stroke who were treated with IV tissue plasminogen activator (tPA), intra-arterial thrombectomy...
17:34 , Jun 2, 2017 |  BioCentury  |  Emerging Company Profile

Prolonging thrombin production

ApcinteX Ltd. is betting that inhibiting an endogenous brake on thrombin production will generate a therapy for hemophilia A and B that can be used by patients who have developed neutralizing antibodies to factor replacement...